Omnix Medical raises $25 million Series C to tackle drug-resistant infections
Israeli biotech secures funding to complete Phase II trials for its novel antimicrobial peptide therapy.
Omnix Medical, an Israeli biopharmaceutical company developing new treatments for antibiotic-resistant infections, has raised $25 million in a Series C funding round co-led by Harel Insurance & Finance and the European Innovation Council (EIC) Fund, the company said on Wednesday. Existing shareholders Entrée Capital, Tal Ventures, Xenia Ventures, and Oriella Limited also took part in the round alongside new external investors, including Prevail Partners and OurCrowd.
Full list of Israeli high-tech funding rounds in 2025
The latest round brings Omnix’s total funding to $43 million since its founding in 2015. The company's lead compound, known as OMN6, is an experimental therapy designed to combat some of the world’s most lethal bacterial pathogens.
The financing will enable Omnix to complete Phase II proof-of-concept trials for OMN6, focusing on life-threatening infections caused by Gram-negative bacteria, particularly Acinetobacter baumannii, a hospital-acquired pathogen often resistant to even the strongest antibiotics.
The new funds will also support regulatory preparations, manufacturing scale-up, and pipeline development of other engineered antimicrobial peptides, or AMPs, the company said.
Unlike traditional antibiotics that target specific bacterial functions, OMN6 acts by destroying bacterial cell membranes directly, a mechanism that allows it to kill bacteria rapidly and independently of genetic resistance.
Related articles:
- Israeli biopharma startup Omnix Medical awarded €10.8 million from EU to fight drug-resistant bacteria
- Omnix Medical completes $8.5 million round to develop next-generation antibiotics for treatment of life-threatening infections
- Sensi.AI raises $45 million Series C to bring AI into the heart of senior care
The compound has been granted Fast-Track and Qualified Infectious Disease Product (QIDP) status by the U.S. Food and Drug Administration.
Dr. Moshik Cohen-Kutner, CEO of Omnix Medical, said the new financing ensures the company can complete critical clinical work and strengthen its infrastructure.
“With the co-leadership of Harel Insurance & Finance and the EIC Fund, and the continued support of our existing shareholders, we now have the resources to complete our Phase II studies, strengthen our regulatory and manufacturing capabilities, and advance our entire pipeline,” he said.
Dr. Niv Bachnoff, Chief Scientific Officer, added that OMN6’s selectivity, rapid pore-forming action, and engineered stability distinguish it from conventional antibiotics. “These qualities not only enable fast and effective treatment but also significantly minimize the likelihood of resistance development,” he said.
